This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?

Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of the most popular ones on the market today, including Ozempic, Wegovy, Mounjaro, and Zepbound. Each of these GLP-1 treatments are developed by either Novo Nordisk or Eli Lilly.Although Novo Nordisk and Eli Lilly are the main players in the GLP-1 arena, a number of other pharmaceutical companies are vying for a spot -- and Wall Street analysts appears particularly bullish on one candidate, Viking Therapeutics (NASDAQ: VKTX).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool